HOME ZACKS RESEARCH FUNDS PORTFOLIO BROKER RESEARCH MARKETS SCREENING VIDEO EDUCATION SERVICES
Earnings    EPS Surprises    Mutual Funds    Options            My Account    Help    
Quote:
Login Free Membership
Search:

Top Zacks Features
Free Membership
Premium Home
Zacks Rank
Real Time Insight
Equity Research
My Portfolio
Stock Screener
Premium Screens
ETFs
Mutual Funds
Options
RSS Feed
Profit from the Pros
Subscription Services
Product Guide
Zacks Premium
Method for Trading
Chart Patterns Trader
Home Run Investor
Insider Trader
Options Trader
Reitmeister Trader
Reitmeister Value
Tactical Trader
Top 10 Stocks
Turnaround Trader
Whisper Trader
Research Wizard
Zacks Ultimate



Zacks Premium
Get profitable stock
picks and timely
market advice in
Zacks.com`s Free
Daily Newsletter!

Free Registration

View the Archive

VRTX: VERTEX PHARMACEUTICALS INC - Stock Quote Enter Ticker:
 

QuoteEstimatesCharts Company ReportsNewsFinancials
  Quote |  Detailed Quotes |  Real Time |  Options Chain |  Greeks Montage

VERTEX PHARMACEUTICALS INC (NASD)
VRTX 36.13 -0.91 (-2.46%) Vol.  1,777,116 16:00 ET

Zacks Rank: 3 - Hold

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.
Zacks Rank Definition Annualized Return
# 1Strong Buy26.83%
# 2Buy18.69%
# 3Hold9.7%
# 4Sell4.03%
# 5Strong Sell1.63%
S&P5009.43%
Zacks Rank Education - Learn more about the Zacks Rank
Zacks Rank Home - All Zacks Rank resources in one place
Zacks Premium - The only way to get access to the Zacks Rank


Day Low - High 36.06 - 37.00
52wk Low - High 26.50 - 58.87
Avg Volume 3,676,821
Industry MED-BIOMED/GENE
Market Cap 7.73 B
Div - Yield 0.00 - 0.00
PE (forward) 11.87
PEG Ratio N/A
Current Year Est. 3.12
EPS Last Year -0.55
Detailed Quote


Premium Research: Stock Analysis

Zacks Rank

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.
Zacks Rank Definition Annualized Return
# 1Strong Buy26.83%
# 2Buy18.69%
# 3Hold9.7%
# 4Sell4.03%
# 5Strong Sell1.63%
S&P5009.43%
Zacks Rank Education - Learn more about the Zacks Rank
Zacks Rank Home - All Zacks Rank resources in one place
Zacks Premium - The only way to get access to the Zacks Rank


Short-Term Rating 1-3 Months
Zacks #1 Rank Strong Buys Zacks Premium
down 3 - Hold
Zacks Recommendation

Zacks Recommendations are an excellent predictor of stock price movement over a 6+ month time frame. The recommendations come from the Zacks Equity Research group which combines the Zacks Rank with the insights from their team of over 50 equity analysts. The result is superior long term stock ratings.

The Zacks Recommendations are split into 3 groups: Outperform, Neutral and Underperform. When Zacks Premium members click on the recommendation it will launch them to the Zacks Equity Research report for the stock. More on these reports below.

Difference Between Zacks Rank and Zacks Recommendation
Zacks Equity Research Home
Zacks Premium - The only way to get access to Zacks Recommendations


Long-Term Rating 6+ Months
All Outperform Rated Stocks Zacks Premium
PREMIUM
Zacks Industry Rank

Which industries are set to outperform or underperform the market? You'll find the answer here. We have broken down all industries into over 200 classifications. Then ranked these industries using the most powerful indicator we know (the Zacks Rank). The higher the industry rank, the better the industry should perform in the future. Once you have found an attractive industry then check out the Rank in Industry to find the best stocks within the industry.

When Zacks Premium members click on the Zacks Industry Rank link they will see the full listing of industries and their current rankings.

About Zacks Industry Rank
Zacks Industry Rank - All current industry ranks.
Zacks Premium - The only way to get access to the Zacks Industry Rank

PREMIUM
Target Price

The Zacks Price Target provides you our expectation for a stocks share price in the next 6 months. These price targets are created by the Zacks Equity Research group to coincide with their recommendations that are also based on a 6 month time horizon.

Zacks Equity Research Home
Zacks Premium - The only way to get access to the Zacks Price Targets

PREMIUM
Equity Research Report

The Zacks Recommendations and Zacks Target Prices are just two of the valuable resources you'll find in the reports created by the Zacks Equity Research group. When Zacks Premium members click on this link they will taken to a page that gives them access to the Zacks Equity Research report for the stock.

Zacks Equity Research Home Zacks Premium - The only way to get access to Zacks Recommendations


Updated as of 02/02/2012
PREMIUM
Get all our stock ratings and recommendations with a Free Trial to Zacks Premium

Premium Research: Industry Analysis

Top Peers Ticker Zacks Rank
VERTEX PHARMACEUTICALS INC VRTX 3
ACADIA PHARMA ACAD 1
ARENA PHARMA ARNA 1
ACORDA THERAPT ACOR 2
Top Peer Analysis Zacks Premium
See all MED-BIOMED/GENE Peers

BROKERAGE RECOMMENDATIONS
Current ABR 2.11
ABR (Last Week) 2.00
# of Recs in ABR 18
Average Target Price 45.93
Rank in Industry 128 out of 179
More Brokerage Recommendations

Zacks Community PeopleAndPicks.com
Community Rating

PeopleAndPicks.com Community Stock Ratings

Rating Recommendation % of Stocks
5 stars Strong Buy 10%
4 stars Buy 20%
3 stars Hold 40%
2 stars Sell 20%
1 stars Strong Sell 10%
0 stars Not Rated  

We believe that a community of investors working together can create a superior stock rating system. Some call this "collective intelligence". Or simply...together we can beat the market!

A stock's Community Rating is calculated based on the aggregate input of the PeopleAndPicks Community. The proportion of buy to sell ratings, recency of analysis, and the average score of the users who rate it favorably all factor into a score of one to five stars.


How do you rate VRTX?
Buy
Sell
Find out what the Zacks Community
thinks of VRTX at PeopleAndPicks.com

NYSE data is at least 20 minutes delayed.
NASDAQ data is at least 15 minutes delayed.

 Interactive Java Charting
 NEW!   Fundamental Charts




 
ZACKS COMMENTARY FOR VRTX
Zacks Blog: Forget Big Pharma, It Is Time For A Biotech ETF
Feb 09, 2012
Cook`s Kitchen : Are Portfolio Managers Irrational?
Feb 08, 2012
Zacks Blog: Incivek Catalyst at Play for Vertex
Feb 03, 2012
Zacks Equity Research: Report for VRTX
Feb 02, 2012
Zacks Blog: Early Approval for Vertex CF Drug
Feb 01, 2012
Zacks Blog: Company News for February 1, 2012
Feb 01, 2012
Zacks Blog: The Zacks Analyst Blog Highlights: Gilead Sciences, Bristol-Myers Squibb, Inhibitex, Vertex Pharmaceuticals and Merck
Jan 20, 2012
Zacks Blog: Gilead Clinches Pharmasset Buy
Jan 19, 2012
More Zacks Commentary
NEWS
Analyst Rating In Review: Vertex Pharmaceuticals Sold Off 3.5% Since Downgraded 7 Days Ago (VRTX) - Story Title - Comtex
Feb 10, 2012
Potential Vertex Pharmaceuticals (VRTX) Trade Has $32.84 Breakeven - Story Title - Comtex
Feb 10, 2012
Vertex Pharmaceuticals Inc. (VRTX) EVP & CFO Ian F Smith sells 9,667 Shares - GuruFocus
Feb 09, 2012
Benzinga`s M&A Chatter for Wednesday February 8, 2012 - Benzinga
Feb 08, 2012
Vertex Pharmaceuticals Crosses Below its 10-day MA (VRTX) - Story Title - Comtex
Feb 08, 2012
Search for 'miracle' renewed - Story Title - Comtex
Feb 07, 2012
Search for 'miracle' renewed - Story Title - Comtex
Feb 07, 2012
Uptrend Call Working As Vertex Pharmaceuticals Stock Rises 25.8% (VRTX) - Story Title - Comtex
Feb 07, 2012
More News
EARNINGS ESTIMATES
  This Quarter
03/2012
Next Quarter
06/2012
This Year
12/2012
Next Year
12/2013
Average Estimate 0.73 0.77 3.12 3.35
Number of Estimates 14 14 17 17
Low Estimates 0.40 0.56 2.17 1.65
High Estimate 1.27 1.08 4.44 5.13
Year Ago EPS -1.05 -0.82 -0.49 3.12
EPS Growth 169.12% 193.82% 736.85% 7.37%

More Estimates

COMPANY DESCRIPTION
Vertex Pharmaceuticals Inc. discovers, develops and markets small molecule drugs that address major unmet medical needs. The company has eight drug candidates in clinical development to treat viral diseases, inflammation, cancer, autoimmune diseases and neurological disorders. Vertex has created its pipeline using a proprietary information-based approach to drug design that integrates multiple technologies in biology, chemistry and biophysics aimed at increasing the speed and success rate of drug discovery. (PRESS RELEASE)

Full Company Report
FINANCIALS
EPS TTM -.55
Sales 1410.63
Net Income 29.57
Price/Earnings N/A
Price/Book 9.82
Price/Cash Flow N/A
Price/Sales 5.48


More Financials

 
About Zacks | Advertise | Affiliate | Media | Careers | Contact Us | Help
Disclaimer | Privacy Policy | Sitemap
NYSE and AMEX data is at least 20 minutes delayed.  NASDAQ data is at least 15 minutes delayed.
Copyright 2012 Zacks Investment Research